- Home
- PMCB vs MYNZ Comparison
PMCB vs MYNZ Comparison
Compare PMCB & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- MYNZ
- Stock Information
- Founded
- PMCB 1996
- MYNZ 2021
- Country
- PMCB United States
- MYNZ Germany
- Employees
- PMCB N/A
- MYNZ N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- MYNZ Health Care
- Exchange
- PMCB Nasdaq
- MYNZ Nasdaq
- Market Cap
- PMCB 11.4M
- MYNZ 10.5M
- IPO Year
- PMCB N/A
- MYNZ 2021
- Fundamental
- Price
- PMCB $1.30
- MYNZ $3.44
- Analyst Decision
- PMCB
- MYNZ Buy
- Analyst Count
- PMCB 0
- MYNZ 3
- Target Price
- PMCB N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- PMCB 15.1K
- MYNZ 177.3K
- Earning Date
- PMCB 03-17-2025
- MYNZ 04-15-2025
- Dividend Yield
- PMCB N/A
- MYNZ N/A
- EPS Growth
- PMCB N/A
- MYNZ N/A
- EPS
- PMCB 1.29
- MYNZ N/A
- Revenue
- PMCB N/A
- MYNZ $893,991.00
- Revenue This Year
- PMCB N/A
- MYNZ $20.94
- Revenue Next Year
- PMCB N/A
- MYNZ $18.01
- P/E Ratio
- PMCB $1.00
- MYNZ N/A
- Revenue Growth
- PMCB N/A
- MYNZ N/A
- 52 Week Low
- PMCB $1.22
- MYNZ $0.18
- 52 Week High
- PMCB $2.55
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- PMCB 33.22
- MYNZ 37.70
- Support Level
- PMCB $1.22
- MYNZ $2.72
- Resistance Level
- PMCB $1.58
- MYNZ $5.34
- Average True Range (ATR)
- PMCB 0.14
- MYNZ 0.55
- MACD
- PMCB -0.04
- MYNZ -0.12
- Stochastic Oscillator
- PMCB 15.59
- MYNZ 27.48
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.